SINGAPORE (Nov 11): iX Biopharma has reported net losses of $776,000 for 1Q17, an improvement of 68% over the net losses of $2.4 million in 1Q16.
Revenue for the quarter to Sept fell by 1% to $1.5 million.
The group’s chemical analysis business, which provides laboratory testing services, contributed $1.45 million, or 99%, to group revenue. The remaining $0.01 million, or 1% of total revenue, arose from its specialty pharmaceutical business.
For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)